<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367419</url>
  </required_header>
  <id_info>
    <org_study_id>S-340-14-6-1-PU-02</org_study_id>
    <nct_id>NCT00367419</nct_id>
  </id_info>
  <brief_title>Use of Erythromycin in Mustard-Induced Bronchiolitis</brief_title>
  <official_title>Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqiyatallah Medical Sciences University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baqiyatallah Medical Sciences University</source>
  <brief_summary>
    <textblock>
      We looked for the effectiveness of low-dose long-term prescription of erythromycin in&#xD;
      mustard-induced bronchiolitis obliterans&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Acute Obliterating Bronchiolitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented chemical exposure&#xD;
&#xD;
          -  Clinical, spirometric and radiological findings were compatible with BO on High&#xD;
             Resolution Computed Tomography (HRCT)&#xD;
&#xD;
          -  Non-responsiveness to high dose bronchodilator therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an&#xD;
             infection that necessitated the use of an antibiotic&#xD;
&#xD;
          -  History of cigarette smoking and occupational exposure to toxic agents of&#xD;
             hypersensitivity to macrolides&#xD;
&#xD;
          -  History of treatment with a systemic antibiotic within 7 days before the start of the&#xD;
             study&#xD;
&#xD;
          -  Any investigational medicine within 4 weeks of the study&#xD;
&#xD;
          -  History of antibiotic injection within 6 weeks before the study&#xD;
&#xD;
          -  Concomitant Theophylline or Carbamazepine, unless their serum concentrations were&#xD;
             regularly monitored&#xD;
&#xD;
          -  Patients who were in the exacerbation phase of their respiratory complications&#xD;
&#xD;
          -  Need to use medications interact with macrolides such as Digoxin, Theophylline and&#xD;
             Carbamazepine&#xD;
&#xD;
          -  Systemic antibiotics&#xD;
&#xD;
          -  Systemic Corticosteroids&#xD;
&#xD;
          -  Admission to the hospital&#xD;
&#xD;
          -  Abnormal kidney or liver function&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Ghanei, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baqiyatallah Medical Sciences University</name>
      <address>
        <city>Tehran</city>
        <zip>19945-546</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>August 21, 2006</study_first_submitted>
  <study_first_submitted_qc>August 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <last_update_submitted>November 4, 2008</last_update_submitted>
  <last_update_submitted_qc>November 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

